deCODE Genetics, the Icelandic company that made a name for himself with his work of personalized medicine before running into a financial pit mud, tried to be optimistic today about his future. At present, it has just enough money to survive in the summer.
But the company says it is restructuring its debt and new investors lined up to channel some money if necessary. DeCODE has focused on two categories of products: new drugs, including drugs, and the diagnosis of Alzheimer potential. In terms of diagnosis, he has six tests on the market, based on research in Iceland, designed to measure the risk of diseases such as heart attack and prostate cancer. Because the tests are already providing income and are likely to provide more fairly quickly, the company said, summarizing the financial results of 08 that he shift focus and resources available to them.
"deCODE is in a very difficult place for now," said Kári Stefánsson, CEO. There are five months, it was the same point. The company was suddenly million short of dollars when Lehman Brothers, which had managed his money, dissolved, but earlier this year, managed to access these auction rate securities and sell them for about $ 12 million to continue function.
0 Komentar